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The IjB kinase (IKK) complex is a key regulator of signal transduction pathways leading to the induction of NF-jB-
dependent gene expression and production of pro-inflammatory cytokines. It therefore represents a major target for
the development of anti-inflammatory therapeutic drugs and may be targeted by pathogens seeking to diminish the
host response to infection. Previously, the vaccinia virus (VACV) strain Western Reserve B14 protein was characterised
as an intracellular virulence factor that alters the inflammatory response to infection by an unknown mechanism. Here
we demonstrate that ectopic expression of B14 inhibited NF-jB activation in response to TNFa, IL-1b, poly(I:C), and
PMA. In cells infected with VACV lacking gene B14R (vDB14) there was a higher level of phosphorylated IjBa but a
similar level of IjBa compared to cells infected with control viruses expressing B14, suggesting B14 affects IKK activity.
Direct evidence for this was obtained by showing that B14 co-purified and co-precipitated with the endogenous IKK
complex from human and mouse cells and inhibited IKK complex enzymatic activity. Notably, the interaction between
B14 and the IKK complex required IKKb but not IKKa, suggesting the interaction occurs via IKKb. B14 inhibited NF-jB
activation induced by overexpression of IKKa, IKKb, and a constitutively active mutant of IKKa, S176/180E, but did not
inhibit a comparable mutant of IKKb, S177/181E. This suggested that phosphorylation of these serine residues in the
activation loop of IKKb is targeted by B14, and this was confirmed using Ab specific for phospho-IKKb.
Citation: Chen RA-J, Ryzhakov G, Cooray S, Randow F, Smith GL (2008) Inhibition of IjB kinase by vaccinia virus virulence factor B14. PLoS Pathog 4(2): e22. doi:10.1371/
journal.ppat.0040022
Introduction
Nuclear factor-jB (NF-jB) is critical for the innate and
adaptive immune responses to infection. Various stimuli,
such as the pro-inﬂammatory cytokines interleukin (IL)-1
and tumour necrosis factor (TNF), activate signaling path-
ways leading to NF-jB-dependent gene expression [1,2].
Several of these signaling pathways converge on the IKK
complex [3–5], and this complex is therefore a prime target
for anti-inﬂammatory drugs. It is also a logical target for
pathogens aiming to minimize the host response to infection.
The IKK complex, or signalosome, comprises a heterodimer
of IKKa and IKKb in association with NF-jB essential
modiﬁer (NEMO also called IKKc) [6,7] and is critical for
NF-jB activation induced by pro-inﬂammatory cytokines [8–
10]. The IKK complex is activated by upstream kinases, such
as transforming growth factor-b (TGFb)-activated kinase-1
(TAK1), which phosphorylates IKKb at Ser177 and Ser181
located in the activation loop [2,4,5]. Once activated, IKKb
phosphorylates the inhibitor of NF-jB( I jBa) [11] to initiate
IjBa degradation. Phosphorylated IjBa (phospho-IjBa)i s
recognized by an F-box/WD protein, b-transducin repeats-
containing proteins (b-TrCP), which functions as a receptor
subunit of the SCF family ubiquitin ligase complex, and
binds to the phosphorylated E3 recognition sequence on
IjBa [12–15]. This poly-ubiquitinated IjBa remains associ-
ated with NF-jB but is degraded selectively via the 26S
proteasome [16]. After IjBa degradation, NF-jB is trans-
located into the nucleus to induce transcription of respon-
sive genes [17].
Poxviruses have developed strategies to modulate impor-
tant cellular signaling pathways to evade host responses [18–
20]. These viruses target many of the primary mediators of
immune system including IL-1, IL-18, interferons (IFNs),
TNF, complement, and chemokines [20–23]. Many of the
genes encoding vaccinia virus (VACV) immunomodulators
show amino acid similarity to host proteins that function in
the immune system. However, others lack such similarity; for
instance, the intracellular virulence factor N1 [24], anti-
apoptotic protein F1 [25,26], and secreted chemokine binding
protein [27].
VACV and other poxviruses interrupt the activity of NF-jB
in several ways [21,28]. One strategy is to secrete proteins
from the infected cell to bind cytokines, chemokines, or IFNs
and prevent these reaching their receptors on cells. Another
strategy is to express intracellular factors to regulate signal-
ing pathways leading to NF-jB activation. Among these
intracellular inhibitors, VACV proteins A52 and A46 antag-
onize IL-1R and toll like receptor (TLR) signaling [29–31] and
N1 is a virulence factor [24] that is reported to interfere with
NF-jB and IRF3 activity [32]. In addition, the crystal structure
of N1 reveals it is a Bcl-2-like protein and N1 was shown to
protect cells from apoptosis [33]. VACV protein K1 also
inhibits NF-jB activation during infection [34]. Lastly,
protein M2 downregulates ERK-mediated NF-jB induction
in virus-infected cells [35].
B14R is one of the few VACV genes that are located in the
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many orthopoxviruses [36], suggesting an important function.
However, B14 lacks sequence identity with proteins from
outside poxviruses. An initial characterization of B14 showed
it is an intracellular virulence factor that is expressed early
during infection and affects the inﬂammatory response to
infection in a murine model by an unknown mechanism [37].
In this study, the mechanism of action of B14 has been
investigated. Data presented show that B14 associates with
and inhibits the activity of the IKK complex and thereby
inhibits NF-jB activation from multiple signaling pathways.
This mechanism of action is consistent with the in vivo
phenotype of a virus lacking the B14R gene [37].
Results
B14 Inhibits Multiple Signaling Pathways Leading to NF-
jB Activation
Bioinformatic analyses indicated that B14 is a member of a
family of poxvirus proteins that include B14, K7, C6, and A52
[38]. Subsequently, the A46 protein was shown to be related
to A52 and was added to this family [29]. Given that proteins
A46 and A52 are intracellular inhibitors of TLR signaling
Figure 1. B14 Inhibits NF-jB Activation
HeLa cells were co-transfected with reporter plasmids for 100 ng of NF-
jB (A and B), ISRE (C), AP-1 (D), and 50 ng of pSV-b-galactosidase in all
cases. pCI-B14 was transfected where indicated and the amount (ng) per
well is shown. The total amount of DNA applied in each reaction was
adjusted to 400 ng using pCI empty vector. These transfected cells were
stimulated with 100 ng/ml of IL-1b, TNFa, IFNa, or 50 ng/ml of PMA for 8
h as indicated. Luciferase activity was measured and normalized to b-
galactosidase intensity in the same well in triplicate wells. (E) HEK 293
cells were co-transfected with pRL-TK and reporter plasmid for NF-jB( &),
ISRE (&), and plasmids expressing GFP, A20, and B14. These cells were
stimulated with 5 lg/ml of poly(I:C) for 12 h and then were lysed to
measure luciferase activity using Dual-specific luciferase assay kit
(Promega). Differences in the fold activation of the indicated reporter
in cells transfected with the empty vector and cells expressing B14 were
analysed by Student’s t-test and the p-values are indicated: * p , 0.05 or
** p , 0.01.
doi:10.1371/journal.ppat.0040022.g001
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Author Summary
Vaccinia virus (VACV) is the live vaccine used to eradicate smallpox
and is also the most intensively studied poxvirus. Like many
poxviruses, VACV produces a wide variety of proteins that inhibit
parts of the host response to infection. Consequently, the virus can
escape destruction by the immune system and be passed on to
additional hosts. Here we report a new VACV immune evasion
mechanism mediated by protein B14, a protein that contributes to
virus virulence. B14 functions by interacting with a cellular protein
called IKKb, which is critical for mounting an innate immune
response to infection, and also plays important roles in cancer and
cell death. B14 prevents IKKb being activated and consequently the
cellular signaling pathway leading to activation of nuclear factor
kappa B (NF-jB) is not induced. Without activation of NF-jB the host
cell cannot produce other molecules that amplify the innate
immune response to infection. This mechanism of action of B14
fits nicely with the observed increase in the host response to
infection by a VACV strain lacking the B14R gene. Lastly, an
increased understanding of how B14 inhibits IKKb function may lead
to development of novel drugs against this important cellular
enzyme.pathways [29–31], the presence of B14 in the same family
suggested that B14 might also act to regulate signaling
pathways leading to NF-jB activation.
To investigate the effect of B14 on NF-jB activation, a
plasmid containing a luciferase reporter gene linked to a NF-
jB-dependent promoter was transfected into HeLa cells and
these cells were stimulated with IL-1b (Figure 1A), TNFa
(Figure 1A), or PMA (Figure 1B). Luciferase activity was
increased greatly by addition of each stimulant but the level
reached was reduced in a dose-dependent manner in the
presence of B14. Similar ﬁndings were observed using HEK
293 cells (unpublished data). Moreover, B14 decreased poly
(I:C)-induced NF-jB dramatically (p-value ¼ 0.0006; 95%
decrease) (Figure 1E). In contrast, B14 did not reduce
luciferase activity from ISRE (Figure 1C) and AP-1 (Figure
1D) reporter genes induced by IFNa and PMA, respectively.
Notably, B14 increased PMA-induced AP-1 activity slightly (p
¼0.02; 1.5-fold increase; Figure 1D). We also observed a small
but signiﬁcant reduction in poly (I:C)-induced ISRE activity
in the presence of B14 (p-value ¼ 0.01; 29% decrease; Figure
1E). However, it is uncertain if these relatively small changes
seen with these reporter assays are relevant biologically. As a
control we also expressed A20, a de-ubiquitinating enzyme
that downregulates NF-jB and IRF3 [39–41] and observed
strong inhibition of both pathways (Figure 1E).
Therefore, B14 is a speciﬁc downregulator of NF-jB but
did not inhibit AP-1 or IRF responsive gene expression. The
fact that B14 inhibits multiple pathways leading to NF-jB
activation suggests that B14 might act at a position at or
downstream of the site at which these pathways converge,
namely the IKK complex.
B14 Associates with the IKK Signalosome
To examine how B14 downregulates NF-jB activation, we
searched for interactions between B14 and potential ligands
using a luminescence-based mammalian interactome map-
ping (LUMIER) assay [42]. Components of the IKK complex
were included in the assay because several pathways leading
to NF-jB activation converge on this complex. HA-tagged
B14 and A20 were transfected into cells together with
different proteins fused with luciferase, and cell extracts
were immunoprecipitated with anti-HA mAb. The immuno-
precipitates were then tested for luciferase activity (Figure
2A). B14 interacted with IKKa, IKKb, and NEMO but not with
TBK1, IKKe, p65, and A20. As expected, A20 showed no
Figure 2. VACV-Expressed B14 Associates with the IKK Signaling Complex
Cells were co-transfected with expression vectors for indicated proteins tagged with HA (A) or FLAG (B) epitopes and the indicated protein fused with
luciferase. The indicated tagged bait protein was immunoprecipated by correspondent monoclonal Ab and then the immune complex was eluted to be
analysed for luciferase activity. Data presented are from one of the three independent experiments.
(C) HeLa cells were infected with vB14 and a cell extract was prepared and analysed by size exclusion chromatography on a Superose 6 column. An
aliquot of each fraction was separated in 4%–12% NuPAGE and analysed by immunoblotting with the indicated Abs. The position of protein size
markers is indicated in kDa at the top.
(D) Extracts from HeLa cells infected with the vDB14 (D) or vB14-HA (HA) were pre-cleared and immunoprecipitated with mAbs against HA, NEMO, and
GSK3b (isotype control). The immunoprecipitated proteins were resolved in 4%–12% NuPAGE and then were analysed by immunoblotting with the Abs
indicated on the right, respectively. Sizes of bands detected are indicated on the left in kDa.
doi:10.1371/journal.ppat.0040022.g002
PLoS Pathogens | www.plospathogens.org February 2008 | Volume 4 | Issue 2 | e22 0003
A Poxviral Inhibitor for IjB Kinaseinteraction with any proteins screened in the assay except
itself [43]. These observations indicated that B14 interacts
with the IKK complex. Previously, VACV protein N1 was
reported to interact with and inhibit the IKK complex [32]
and therefore FLAG-tagged N1 was also included in this
assay. Surprisingly, no interaction between N1 and IKKa,
IKKb, or NEMO was observed (Figure 2B), although FLAG-
B14 and IKKa each co-precipitated with the IKKs. FLAG-GFP
was included as a negative control and did not bind to the
IKKs. Collectively, these data show that B14, but not N1,
associates with the IKK signalosome.
To investigate these protein interactions further, we
fractionated VACV-infected cell extracts by size exclusion
chromatography(SEC)andblottedthefractionswithantibody
to B14. B14 eluted in two peaks corresponding to approx-
imately 160 kDa and 700–900 kDa, despite having a mono-
meric size of 17 kDa. Given that the IKK complex also has a
mass of between 700–900 kDa [1], we immunoblotted the
column fractions with antibodies to IKK components and
foundthattheIKKcomplexco-puriﬁedwiththeﬁrstB14peak
(Figure 2C). The column fractions were also blotted with Ab to
N1 and this showed that N1 eluted with a mass of approx-
imately 60–70 kDa (Figure 2C), quite distinct from the IKK
complex and also distinct from the expected position of the
Figure 3. B14 Binds to the IKK Complex via IKKb
(A) Wild type, IKKa null, and IKKb null MEF cells were infected with vB14-HA and cell extracts were immunoprecipitated using anti-NEMO mAb. The
immunocomplex was resolved by SDS-PAGE (12% gel) and analysed by immunoblotting using the indicated Abs.
(B) Cell extracts from vB14-HA-infected MEFs were prepared and analysed by SEC on a Superose 6 column. Proteins from each fraction were precipitated
using trichloroacetic acid and 15% of the sample was separated in a 12% SDS-PAGE and analysed by immunoblotting using the indicated Abs.
doi:10.1371/journal.ppat.0040022.g003
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puriﬁed with the IKK complex in the VACV-infected cell
lysates.
The possible interaction between B14 and the IKK complex
was investigated further by immunoprecipitation. HeLa cells
were infected with a VACV strain expressing an HA-tagged
version of B14 (vB14-HA) or VACV lacking gene B14R
(vDB14) [37], and cytoplasmic extracts were prepared. B14-
HA was immunoprecipitated with anti-HA mAb and immu-
noprecipitates were analysed by immunoblotting with Abs
against IKKa and IKKb, NEMO, or HA (Figure 2D). The anti-
HA mAb precipitated B14-HA together with IKKa, IKKb, and
NEMO from the vB14-HA infected cell lysates (Figure 2D,
lane 4). The interaction between B14 and the IKK complex
was also seen in the reciprocal immunoprecipitation using
antibody to NEMO (Figure 2D, lanes 5 and 6) and anti-IKKa/b
(unpublished data). In contrast, B14 and the IKK complex
were not co-immunoprecipitated with a control mAb against
glycogen synthase kinase (GSK)-3b (Figure 2D, lanes 7 and 8).
In summary, B14 and the IKK complex co-puriﬁed and co-
precipitated when each component was expressed at natural
levels.
To identify which of the IKK components interacts with
B14, mouse embryo ﬁbroblasts (MEFs) lacking IKKa or IKKb
were analysed as above for HeLa cells (Figure 3). In vB14-HA-
infected wild type MEFs B14 co-precipitated with the IKK
complex (Figure 3A, lane 4). In the absence of IKKa or IKKb,
the anti-NEMO mAb still precipitated a complex of IKKb-
NEMO and IKKa-NEMO, respectively (lanes 5 and 6).
However, B14 was co-precipitated from IKKa but not IKKb
null MEFs, indicating that B14 was incorporated in the IKKb-
NEMO complex (lane 5) and that IKKb was needed for B14 to
be part of the IKK complex. As a control, an anti-FLAG mAb
did not immunoprecipitate any proteins (Figure 3A, lanes 7–
9). The interaction between B14 and IKKb was also
investigated by SEC of extracts from wild type, IKKa,o r
IKKb null MEFs (Figure 3B). B14 only co-puriﬁed with the
IKK complex of 700–900 kDa when IKKb was present, but was
present in the second peak of 160 kDa in all samples. So, IKKb
is necessary for B14 to co-purify or co-precipitate with the
IKK complex.
IKK Activity Is Downregulated by B14
Upon stimulation, the IKK complex phosphorylates IjBa
and this is then removed quickly via the proteasome system.
Therefore, we examined the level of IjBa in cells stimulated
with TNFa in the presence and absence of B14 (Figure 4). The
amount of IjBa was reduced dramatically at 20 min after
TNF treatment but had recovered to the original level by 50
min. However, in the presence of B14 the level of IjBa was
greater at 20 min post-stimulation with TNF. Thereafter, the
level of IjBa recovered to that before stimulation. Equal
loading of samples was demonstrated by blotting for a-
tubulin. Therefore, B14 increased IjBa stability after TNF
stimulation, implying a negative effect on IKK activity.
The above experiment was performed in cells expressing
B14 after transfection. To investigate whether the endoge-
nous levels of B14 could affect IKK activity during virus
infection, the phosphorylation status of IjBa was investigated
in cells infected with VACV strains that do or do not express
B14. Cells were infected with wild type (vB14), deletion
mutant (vDB14), or revertant (vB14-rev) viruses [37] at 2 p.f.u./
cell and at 2 and 4 h p.i., cytoplasmic fractions were prepared
and analysed by immunoblotting (Figure 5). The level of IjBa
was indistinguishable in infected or uninfected cells, and
similarly there was no difference following infection with
viruses that did or did not express B14. However, following
infection by all viruses, the level of phospho-IjBa was
increased, but the increase was noticeably higher in cells
infected with vDB14, compared to vB14 and vB14-rev. To
show that each virus caused equivalent infection, cell extracts
were immunoblotted with antibody to the VACV intracellular
protein N1 [24], and N1 was detected at similar levels in each
sample at 2 h p.i. and at slightly higher levels in each sample
later during infection (4 h) (Figure 5, bottom panel, lanes 2–4
and 6–8). In contrast, B14 was present in vB14- and vB14-rev-
infected cells only. As expected, each VACV protein was
absent in mock-infected cells. This suggested that B14
reduces IKK activity during VACV infection.
Figure 4. The Effect of B14 on IjBa
B14 was expressed in HeLa cells by transfection and the cells were
treated with TNFa for the indicated times. Then TNF was washed away
and extracts were prepared and analysed by immunoblotting with the
indicated Abs. Cell lysates (15 lg per lane) were resolved by SDS-PAGE
(15% gel) and analysed by immunoblotting with the Abs indicated on
the right. Sizes of bands detected are indicated on the left in kDa.
doi:10.1371/journal.ppat.0040022.g004
Figure 5. B14 Reduces the Phosphorylation of IjBa in VACV-Infected
Cells
Cytoplasmic extracts were prepared from HeLa cells at the indicated
times after mock-infection (M) or infection with vB14 (W), vDB14(D), and
vB14-rev (R) at 2 p.f.u. per cell. Cytosolic proteins (15 lg per lane) were
resolved by SDS-PAGE (15% gel) and analysed by immunoblotting with
the Abs indicated on the right. Sizes of bands detected are indicated on
the left in kDa.
doi:10.1371/journal.ppat.0040022.g005
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VACV-encoded NF-jB inhibitors was investigated next using
an in vitro kinase assay. Plasmids expressing TRAF2 or HA-
tagged IKKb were co-transfected with or without pCI-B14.
TRAF2 acts as an intracellular stimulator of IKK activity.
Extracts from transfected cells were immunoprecipitated
with anti-HA mAb. The activity of the immunoprecipitated
IKK complex was studied using a synthetic IjBa peptide
substrate and
32P-c-ATP followed by SDS-PAGE and auto-
radiography. Notably, the level of the phospho-IjBa peptide
was reduced in the presence of B14, indicating B14 inhibited
IKK activity (Figure 6). Coomassie blue staining of the SDS-
polyacrylamide gel indicated that similar amount of the
immunoprecipitated HA-IKKb and substrate peptides were
applied in the assay (Figure 6, lower panels).
To study the effect of B14 on IKK activity further, the IKK
complex was activated by overexpression of either IKKa or
IKKb (Figure 7A), and B14 was found to inhibit this activation
signiﬁcantly and in a dose-dependent manner (Figure 7A).
This indicated that B14 acts at, or downstream of, the IKK
signalosome. The site of action was investigated further using
IKK constitutively active mutants, IKKa SS/EE and IKKb SS/
EE that contain mutations in the activation loop [2] (Figure
7B). B14 inhibited IKKa SS/EE signiﬁcantly and in a dose-
dependent manner. In contrast, there was only a small (15%)
reduction of IKKb SS/EE-induced NF-jB activation in the
presence of the highest amount of B14. These ﬁndings imply
that once IKKb is activated, B14 can no longer prevent NF-jB
activation and also suggest a model in which B14 inhibits
activation of the IKK complex by preventing phosphorylation
of IKKb in the activation loop.
This hypothesis was tested directly by using Ab to detect
IKKb that has been phosphorylated in the activation loop at
serine 177 and 181 (Figure 8). HA-tagged IKKb was trans-
fected into 293 T cells either alone or together with
increasing concentrations of B14. In the absence of trans-
fected HA-IKKb no phospho-IKKb was detected, but after
addition of HA-IKKb, phospho-IKKb was observed easily and
was reduced in a dose-dependent manner as the concen-
tration of B14 increased. Notably, while the amount of
phospho-IKKb decreased in the presence of B14, the amount
of total HA-IKKb remained fairly constant and blotting for
tubulin conﬁrmed equal loading of samples. Therefore, B14
inhibits NF-jB activation by preventing phosphorylation of
IKKb in the activation loop.
Figure 7. The Effect of B14 on IKKa and IKKb-Induced NF-jB Activation
HEK 293 cells were co-transfected with reporter plasmids for NF-jB (90
ng), TK-RhL as internal control (10 ng), and the indicated amount of
plasmids expressing either wild type IKKa or IKKb (A), constitutively
active IKKa or IKKb (B), or B14 (A and B). The total amount of DNA
applied in each reaction was adjusted to 500 ng using pCI empty vector.
After 24 h, the cells were lysed and the activities of both luciferases were
measured using Dual-specific luciferase assay kit (Promega) in triplicates.
Differences in the fold activation of the NF-jB reporter induced by the
indicated IKK subunit in cells transfected with the empty vector and cells
expressing B14 were analysed by Student’s t-test and the p-values are
indicated: * p , 0.05 or ** p , 0.01.
doi:10.1371/journal.ppat.0040022.g007
Figure 6. B14 Inhibits IKK-Mediated Phosphorylation of IjBa
HEK 293 cells were transfected with plasmids expressing the indicated
proteins (2 lg of vectors expressing B14, TRAF2, and HA-IKKb). The
empty vector pCI was used to adjust the total DNA added to 6 lg per
reaction per 10 cm dish. After 24 h, 1.5 mg of cell extracts were
immunoprecipitated with anti-HA mAb for 3 h at 4 8C. The immune
complex was incubated with 5 lgo fI jBa peptide and 5 lCi
32PcATP for
10 min at 30 8C. The kinase assay was terminated by adding protein
loading buffer and the mixture was resolved and analysed by Coomassie
staining followed by autoradiography (top panel, kinase assay). Protein
markers (kDa) were indicated on the left. N.S. indicates non-specific band.
doi:10.1371/journal.ppat.0040022.g006
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In this study, VACV protein B14 is shown to inhibit the IKK
complex and to downregulate NF-jB-dependent gene ex-
pression, which is crucial for the innate and adaptive immune
response to infection [3,4]. Our previous in vivo study, using
recombinant VACVs that do or do not express B14,
demonstrated B14 is an intracellular virulence factor that
modulates the inﬂammatory response in vivo [37]. The
activity of B14 described here is consistent with this
phenotype: downregulation of NF-jB-dependent expression
of pro-inﬂammatory cytokines will alter recruitment of
inﬂammatory cells to sites of infection and so diminish the
ability of the host to ﬁght infection. Notably, a virus lacking
the B14R gene was attenuated compared to parental virus
[37].
The IKK complex is critical for activation of NF-jB [3,44–
46] and therefore is a logical target for modulation by
pathogens [4,47]. B14 is one of several VACV proteins that
inhibit signaling pathways leading to NF-jB activation, but
these proteins all have non-redundant functions because
when the gene encoding each inhibitor is deleted individu-
ally, the deletion mutant displays an in vivo phenotype
[24,29–31,37]. Therefore, these proteins must each have
distinct functions. In this regard, B14 differs from A46 and
A52 in that it targets a broader array of immune signaling
pathways; for instance, A46 and A52 inhibit IL-1 but not
TNF-induced signaling, whereas B14 inhibits both (Figure
1A). Also A46 and A52 target the signaling pathways upstream
of the IKK complex [29–31], whereas B14 targets the activity
of the IKK complex. B14 also differs from N1 in that N1 was
reported to inhibit signaling pathways leading to NF-jB
activation [32] and to IFN responses via TBK1 [32], whereas
B14 did not inhibit IFN responses induced by either IFNa or
poly (I:C) (Figure 1E). N1 was reported to target to the IKK
signalosome by binding to the kinase complex when both
components were overexpressed [32]. However, three inde-
pendent experiments shown here contradict this: ﬁrst, N1 did
not bind to IKK components in the LUMIER assay (Figure
2B); second, N1 did not co-purify with IKK during bio-
chemical fractionation of infected cells (Figure 2C); and third,
N1 did not co-precipitate with IKK components using the
anti-NEMO mAb (unpublished data). In addition, we showed
previously that under the conditions tested N1 did not affect
NF-jB activation in VACV-infected cells [33]. Therefore, B14,
but not N1, associates with the IKK complex and thereby
inhibits NF-jB responsive gene expression.
Concerning the site of action of B14, it is clear that B14
shuts down expression of reporter genes with NF-jB-
responsive promoters in response to multiple stimuli (Figure
1) and that within infected cells the overall level of IjBa is not
altered by virus infection (Figure 5) or by the expression of
B14 in resting cells (Figure 4). However, in the presence of
B14 there is a reduced level of phospho-IjBa in the infected
cell lysates (Figure 5) and a reduced degradation of IjBa in
TNFa-stimulated cells. These ﬁndings suggest a possible effect
of B14 on the IKK activity. Direct evidence for the reduced
phosphorylation of IjBa by IKK in the presence of B14 was
provided by an in vitro kinase assay using a synthetic IjBa
peptide substrate and IKK that had been immunoprecipi-
tated from cells (Figure 6). Therefore, the mechanism of
action of B14 lies upstream of IjBa phosphorylation.
Consistent with this, B14 was found to co-purify with the
IKK complex from infected cells and to co-precipitate with
the IKK complex using speciﬁc antibodies either against
tagged B14, NEMO (Figures 2 and 3), or against IKKa/b
(unpublished data). Notably, the assembly of the IKK complex
was not interrupted by B14. Furthermore, use of IKK null
MEFs revealed that IKKb is the target of B14 in the complex
and B14 did not bind to or disrupt the IKKa-NEMO complex
(Figure 3B). These ﬁndings indicate that the inhibitory effect
of B14 on the activity of the IKK complex is not due to
disassembly of the IKK complex.
B14 inhibited NF-jB activation driven by overexpression of
either IKKa or IKKb (Figure 7A) or by expression of the
constitutively active IKKa SS/EE mutant in which the ser176
and ser180 in the activation loop were mutated to glutamic
acid (Figure 7B). In contrast, B14 was unable to inhibit NF-jB
gene expression by a similar constitutively active IKKb SS/EE
mutant (Figure 7B), indicating IKKb but not IKKa is the
target for B14. Furthermore, B14 associated with the IKK
complex via IKKb (Figure 3) and inhibited phosphorylation
of IKKb in the activation loop (Figure 8), thereby down-
regulating the activity of the IKK complex. However, once the
IKKb subunit is activated, B14 may not be inhibitory.
B14 co-puriﬁed with the IKK complex but was also present
in a 160-kDa complex, much larger than the mass of
monomeric B14 (17.3 kDa). Consistent with these ﬁndings,
recombinant B14 made in Escherichia coli was oligomeric
(unpublished data). Whether B14 is the only protein in the
160-kDa complex or whether it is complexed with other
unidentiﬁed cellular or viral protein(s) is unknown. However,
its presence in this complex suggests B14 might have
function(s) additional to that described here. For instance,
the slight increase of PMA-induced AP-1 activity in the
presence of B14 (Figure 1D) may result from interaction of
B14 with an unidentiﬁed protein(s). Alternatively, this may be
Figure 8. B14 Inhibits Phosphorylation of IKKb on Ser 177/181
HEK 293T cells were transfected with vectors expressing B14 (3, 1.2, and
0.6 lg) and HA-IKKb (2 lg). The empty vector pCI was used to adjust the
total DNA added to 5 lg per reaction per 6 cm dish. After 24 h, cell
l y s a t e sw e r er e s o l v e db yS D S - P A G E( 1 5 %g e l )a n da n a l y s e db y
immunoblotting using the Abs indicated on the right (the anti-HA
mAb was used to detect total HA-IKKb). Sizes of bands detected are
indicated on the left in kDa.
doi:10.1371/journal.ppat.0040022.g008
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genes that negatively regulate AP-1 activity. There is ample
precedent for small VACV proteins having more than one
immunomodulatory activity. For instance, protein A52 is
both a TLR inhibitor and an activator of p38 kinase to
modulate IL-10 [48].
In summary, VACV virulence factor B14 inhibits the IKK
signalosome by preventing phosphorylation of IKKb in the
activation loop, resulting in inhibition of NF-jB-dependent
gene expression. This mechanism of action ﬁts with the
observed increased inﬂammatory response in vivo to infec-
tion with a virus lacking gene B14R [37]. Overall our ﬁndings
reveal a novel strategy used by VACV to modulate cellular
signaling pathways to aid viral immune evasion. The B14 may
be an interesting target to develop anti-inﬂammatory
therapeutics directed against the IKK complex.
Materials and Methods
Cell culture. Human embryonic kidney (HEK) 293 cells (a gift from
Dr. Paul Farrell, Imperial College London), wild type, IKKa null, and
IKKb null MEF cells (provided by Dr. Michael Karin, UCSD) were
cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM, Gibco BRL)
supplemented with 10% heat-treated foetal bovine serum (FBS, heat-
treated at 56 8C for 30 min, Harlan Sera-Lab), 50 IU/ml penicillin and
50 lg/ml streptomycin (Gibco BRL) and 2 mM L-glutamine (Gibco
BRL). HeLa cells were maintained in Minimum Essential Medium
(MEM Gibco BRL) supplemented with 1 x non-essential amino acid
solution (Sigma) and identical chemicals as DMEM. The cells were
incubated in a humidiﬁed incubator (Heraeus) with 5% CO2.
Plasmids, antibodies, and recombinant VACVs. Expression vectors,
VACV strains that do or do not express B14, and rabbit anti-serum
against B14 have been described previously [37]. Plasmids expressing
IKKs and IKK constitutively active mutants were kindly provided by
Dr. Alain Chariot (University of Lie `ge) and Dr. Richard Gaynor (Lilly
Corporate Center), respectively. Reporter and TRAF2 plasmids were
gifts from Dr. Andrew Bowie (Trinity College Dublin). Anti-IKKc
(NEMO) (BD Biosciences), anti-HA (Cambridge Biosciences), anti-
GSK3b (BD Biosciences) mAbs were used for immunoprecipitation or
immunoblotting. For immunoblotting, rabbit polyclonal anti-IKKa
(Cell Signaling), anti-IKKa/b (Santa Cruz), NEMO (Cell Signaling), and
IjBa (Santa Cruz) were used. In addition, murine mAb anti-P-IjBa
(Cell Signaling), a-tubulin, IKKa and IKKb (Upstate) were used. The
anti-N1 polyclonal Ab was described previously [24]. Lastly, rabbit
mAb against phospho-IKKa/b (16A6, Cell Signaling) was used to
detect IKKb that is phosphorylated at Ser177/181.
Reporter assay. HeLa cells (8310
4 per well) were seeded and then
transfected with 100 ng of reporter plasmids, 50 ng of pSV-b-
galactosidase (Promega), and the indicated amount of expression
vectors with FuGENE 6 (Roche). The total amount of DNA (400 ng)
was kept constant by supplementation with pCI (Promega). After
overnight incubation, the transfected cells were simulated with 100
ng/ml of IL-1b, TNFa (Peprotech), or 50 ng/ml of PMA (Sigma) for 8 h.
Cells were harvested in passive lysis buffer (Promega), and the relative
stimulation of NF-jB activity was calculated by normalizing luciferase
activity with b-galactosidase activity.
HEK 293 cells (6 3 10
4 per well) were seeded into 24-well tissue
culture plates overnight before transfection. Reporter plasmids (90
ng), 10 ng of pTK-Renilla luciferase (pRL-TK, a gift from Dr. Andrew
Bowie), and the indicated amount of expression vectors were
delivered into cells with FuGENE 6. The total amount of DNA (500
ng) was kept constant by supplementation with pCI (Promega). After
24 h, cells were harvested in passive lysis buffer (Promega), and the
relative stimulation of NF-jB-dependent gene expression was
calculated by normalizing luciferase activity with Renilla luciferase
intensity. In case of stimulations, the cells were incubated with stimuli
described previously and 5 lg/ml of poly (I:C) (Invitrogen) for 12 h
before lysis.
In all cases, data shown are from one of three to ﬁve independent
experiments with similar qualitative results. Data from experiments
performed in triplicate are expressed as means 6 SD.
Immunoprecipitation and immunobloting. HeLa cells in 10-cm
dishes were infected by vB14-HA or vDB14 (10 p.f.u. per cell). At 4 h
p.i., the infected cells were washed once with ice-cold PBS and lysed
with IP buffer (50 mM HEPES [pH 7.5], 100 mM NaCl, 1 mM EDTA,
10% [v/v] glycerol, 0.5%[v/v] Nonidet P-40 containing 1 mM phenyl-
methylsulphonyl ﬂuoride, 0.01% [v/v] aprotinin, and 1 mM sodium
orthovanadate). For immunoprecipitation, the indicated antibodies
were pre-incubated with protein G-Sepharose (Amersham) at 4 8C for
1 h. Then equal amounts of the beads were added and incubated with
the cell lysates overnight at 4 8C. The immune complexes were
washed, boiled with 30 ll of 5 x sample buffer, and analysed by
immunoblotting.
Proteins were resolved and transferred to nitrocellulose mem-
branes (Hybond ECL, Amersham). After transfer, the membranes
were rinsed once in PBS and then incubated with blocking buffer
(PBS containing 5% Marvel milk powder) for 30 min at RT. The
primary Ab was added to the blocking buffer and incubated for 1 h
on a rocking platform. The membranes were washed ﬁve times, for 6
min, with PBS, and then HRP-conjugated secondary Ab (Sigma) was
added in blocking buffer. After 45-min incubation, the membranes
were washed as above and then incubated with chemiluminescence
reagent (ECL, Amersham) for signal detection. The membranes were
wrapped in Saran wrap and exposed to X-ray ﬁlm (Kodak).
Size exclusion chromatography. At 4 h p.i., the infected cells were
washed once with ice-cold PBS and lysed with CE buffer (10 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 10 mM KCl,
0.1 mM EDTA (pH 8.0), 0.1 mM EGTA, 1 mM DTT, 0.05 % NP-40, 20
mM b-glycerophosphate, 1 mM Na3VO4, 1 x protease inhibitor
cocktail II (CalBio) for 30 min at 4 8C. The extract was centrifuged at
10,000 x g for 1 h at 4 8C. Five hundred ll of the supernatant was
loaded onto a Superose 6 gel ﬁltration column (Amersham) that had
been equilibrated in gel ﬁltration (GF) buffer (25 mM Tris-HCl [pH
7.6], 150 mM NaCl, 0.2% NP-40, 1 mM DTT). Approximately 10%–
15% of each fraction was analysed by SDS-PAGE followed by
immunoblotting with the indicated Ab. The column was calibrated
in the GF buffer using protein standards kits from Amersham.
In vitro kinase assay. HEK 293 cells were transfected using the
indicated vectors overnight and lysed in lysis buffer (20 mM Tris
[pH 7.4], 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-
100, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1
mM Na3VO4,1lg/ml leupeptin, and 1 mM phenylmethylsulfonyl
ﬂuoride). The HA-tagged IKK proteins in the cell lysate were
immunoprecipitated using anti-HA mAb. The precipitate was
washed three times in lysis buffer and twice in kinase buffer (20
mM Hepes/KOH [pH 7,4], 25 mM b-glycerophosphate, 2 mM
dithiothreitol, 20 mM MgCl2). The kinase assay was performed in a
ﬁnal volume of 20 ll of kinase buffer containing 10 lM ATP, 5 lCi
of [c-
32P] ATP and 1 lg of IKK substrate peptide (Upstate) derived
from IjBa sequence (KKKKERLLDDRHDSGLDSMKDEE). After
incubation for 10 min at 30 8C, the reaction was stopped by the
addition of 53 SDS sample buffer. Proteins were separated by SDS-
PAGE and stained by Coomasie blue.
32P-labelled proteins were
visualized by autoradiography.
LUMIER. For LUMIER assays [42], 293 ET cells were transfected
with a pair of putative interactors fused to Renilla luciferase or HA/
FLAG antibody tags. Post-nuclear supernatants from cells lysed in IP
buffer (10% glycerol, 150 mM NaCl, 20 mM Tris-HCl [pH 7.4], 0.1 %
Triton-X100, and inhibitors) were incubated with HA or FLAG
agarose (Sigma). After washing, proteins were eluted for 30 min with
150 lg/ml FLAG peptide or 100 lg/ml HA peptide in Renilla lysis
buffer (Promega). The ratio between luciferase activity in eluates and
lysates is presented as fold binding over a control reaction.
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